Johnny Yasuo Nagasawa

This inventor holds 27 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Cylene Pharmaceuticals, Inc., Metacrine, Inc., Seragon Pharmaceuticals, Inc.. Active years: 2007-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Johnny Yasuo Nagasawa. Retrieved from https://idiyas.com/inventor/johnny-yasuo-nagasawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 18)

% Patents Active = 81.5

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 20)

Average Co-Inventor Count = 4.5

ph-index = 10

Forward Citations = 267(Granted Patents)

Company Filing History:

6 out of 21

Cylene Pharmaceuticals, Inc.

Seragon Pharmaceuticals, Inc.

Aragon Pharmaceuticals, Inc.

patents

6. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

7. 1 out of 3,745

Bristol-Myers Squibb Compnay

patents

8. 1 out of 12

Senhwa Biosciences, Inc.

patents

Years Active: 2007-2022

Loading Chart...

Areas of Expertise:

Farnesoid X Receptor Agonists

Estrogen Receptor Modulators

Quinolone Analogs

Heterocyclic Compounds

Protein Kinase Modulators

Fluorinated Estrogens

Oxindole Compounds

Akt Inhibitors

Glucocorticoid Receptor Modulators

Pharmaceutical Applications

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11236071 - Farnesoid X receptor agonists and uses thereof (2022-02-01),

2. 11214538 - Farnesoid X receptor agonists and uses thereof (2022-01-04),

3. 10961198 - Farnesoid X receptor agonists and uses thereof (2021-03-30),

4. 10927082 - Farnesoid X receptor agonists and uses thereof (2021-02-23),

5. 10703712 - Farnesoid X receptor agonists and uses thereof (2020-07-07),

6. 10626081 - Farnesoid X receptor agonists and uses thereof (2020-04-21),

7. 10053451 - Heterocyclic estrogen receptor modulators and uses thereof (2018-08-21),

8. 9868704 - Estrogen receptor modulators and uses thereof (2018-01-16),

9. 9845291 - Estrogen receptor modulators and uses thereof (2017-12-19),

10. 9499538 - Estrogen receptor modulators and uses thereof (2016-11-22),

11. 9399646 - Estrogen receptor modulators and uses thereof (2016-07-26),

12. 9193714 - Fluorinated estrogen receptor modulators and uses thereof (2015-11-24),

13. 9187460 - Estrogen receptor modulators and uses thereof (2015-11-17),

14. 9078871 - Estrogen receptor modulators and uses thereof (2015-07-14),

15. 8853234 - Quinolone analogs and methods related thereto (2014-10-07),

Title: **Innovative Contributions of Johnny Yasuo Nagasawa in the Field of Pharmacology**

Introduction

Johnny Yasuo Nagasawa, based in San Diego, CA, is a prolific inventor with an impressive portfolio of 27 patents. His work primarily focuses on advancements in pharmacology, particularly concerning farnesoid X receptor agonists which play a significant role in treating various medical conditions.

Latest Patents

Among his latest innovations, Nagasawa has developed several patents on farnesoid X receptor agonists. These patents detail compounds that function as agonists for the farnesoid X receptor. They cover methods of synthesizing these compounds, formulations for pharmaceutical compositions, and ways to employ these compounds in treating disorders linked to farnesoid X receptor activity. This research underscores his commitment to addressing crucial medical needs through innovative drug development.

Career Highlights

Throughout his career, Johnny Nagasawa has made significant strides in the pharmaceutical industry. He has worked with reputable companies such as Cylene Pharmaceuticals, Inc. and Metacrine, Inc., contributing to projects that push the boundaries of medical science. His extensive patent portfolio reflects his dedication to innovation and his expertise in pharmacology.

Collaborations

Nagasawa's collaborative efforts have also been noteworthy. He has worked alongside esteemed colleagues, including Nicholas D. Smith and Steven P. Govek. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their collective research in the pharmaceutical sector.

Conclusion

In conclusion, Johnny Yasuo Nagasawa exemplifies the spirit of innovation in the pharmaceutical industry. His numerous patents on farnesoid X receptor agonists signify critical advancements that could lead to improved treatments for various health conditions. His collaboration with notable industry professionals and contributions to acclaimed companies like Cylene Pharmaceuticals and Metacrine underscore his importance as an inventor and innovator in the field.

Profile summary based on public USPTO records.